Kent Wallner1, Stephen Sutlief2, Carl Bergsagel2, Gregory S Merrick3. 1. Radiation Oncology Service, Department of Veterans Affairs Medical Center, Seattle, United States. Electronic address: Kent.wallner@va.gov. 2. Radiation Oncology Service, Department of Veterans Affairs Medical Center, Seattle, United States. 3. Urologic Research Institute, Wheeling Jesuit University, United States.
Abstract
PURPOSE: Some investigators have reported severe rectal complications after brachytherapy. Due to the low number of such events, their relationship to dosimetric parameters has not been well characterized. METHODS AND MATERIALS: A total of 3126 patients were treated with low dose rate brachytherapy from 1998 through 2010. 2464 had implant alone, and 313 had implant preceded by 44-46Gy supplemental external beam radiation (EBRT). Post-implant dosimetry was based on a CT scan obtained on the day of implant, generally within 30min of the procedure. Every patient's record was reviewed for occurrence of rectal complications. RESULTS: Eight of 2464 patients (0.32%) treated with brachytherapy alone developed a radiation-related rectal fistula. Average prostatic and rectal dose parameters were moderately higher for fistula patients than for patients without a severe rectal complication. For instance, the average R100 was 1.2±0.75cc for fistula patients, versus 0.37±0.88cc for non-fistula patients. However, the fistula patients' values were well within the range of values for patients without a rectal complication. Four patients had some attempt at repair or reconstruction, but long-term functional outcomes were not favorable. CONCLUSIONS: Rectal fistulas are a very uncommon potential complication of prostate brachytherapy, which can occur even in the setting of acceptable day 0 rectal doses. Their occurrence is not easily explained by standard dosimetric or clinical factors. Published by Elsevier Ireland Ltd.
PURPOSE: Some investigators have reported severe rectal complications after brachytherapy. Due to the low number of such events, their relationship to dosimetric parameters has not been well characterized. METHODS AND MATERIALS: A total of 3126 patients were treated with low dose rate brachytherapy from 1998 through 2010. 2464 had implant alone, and 313 had implant preceded by 44-46Gy supplemental external beam radiation (EBRT). Post-implant dosimetry was based on a CT scan obtained on the day of implant, generally within 30min of the procedure. Every patient's record was reviewed for occurrence of rectal complications. RESULTS: Eight of 2464 patients (0.32%) treated with brachytherapy alone developed a radiation-related rectal fistula. Average prostatic and rectal dose parameters were moderately higher for fistulapatients than for patients without a severe rectal complication. For instance, the average R100 was 1.2±0.75cc for fistulapatients, versus 0.37±0.88cc for non-fistulapatients. However, the fistulapatients' values were well within the range of values for patients without a rectal complication. Four patients had some attempt at repair or reconstruction, but long-term functional outcomes were not favorable. CONCLUSIONS:Rectal fistulas are a very uncommon potential complication of prostate brachytherapy, which can occur even in the setting of acceptable day 0 rectal doses. Their occurrence is not easily explained by standard dosimetric or clinical factors. Published by Elsevier Ireland Ltd.